Key points for me:Covalent bonding of the antigen. We are the...

Key points for me:
Covalent bonding of the antigen. We are the only next generation platform with covalent bonding. Significant

The platform was developed at U-Penn by the inventors of Car-t. We have the exclusive license and access to the best minds in the space, including Oxford and the spy tag tech.

Ambitious clinical program to develop and prove the tech will put us in a leadership position in next gen Car-T and many value opportunities.

We have some secret technology under development in cell therapy (Carina) which they keep hinting at but can’t talk about. I think this has the potential to enhance the efficacy of Car-t in solid tumors.

Overall this looks super positive in all directions. I think I’ll double down and hang on for five years.

GLTAH’s